Epidemiology and radiological geometric assessment of pituitary macroadenomas: population‐based study

Gruppetta, Mark; Vassallo, Josanne

doi:10.1111/cen.13064

Cited by 26 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to previous cross‐sectional studies, the distribution of patients between the three size groups in this study does not reflect the distribution in the prolactinoma patient population: Giant prolactinomas constitute 2%–6% of prolactinomas in men, 27,42 and not 18% as in our cohort. This discrepancy is probably the result of a referral bias: Being a tertiary referral centre, our patients usually suffer from larger and more aggressive lesions.…”

Section: Discussioncontrasting

confidence: 68%

Long‐term response to cabergoline and multi‐modal treatment in men with macroprolactinoma: Does size really matter?

Rudman

Duskin-Bitan

Manisterski

et al. 2021

Clinical Endocrinology

View full text Add to dashboard Cite

Objective To study the outcome of men with macroprolactinoma following cabergoline treatment based on tumour size. Design Retrospective cohort study. Methods The study included 94 men, divided into three groups according to adenoma diameter: 10–19 mm (Group A, n = 36); 20–39 mm (Group B, n = 41); or ≥40 mm (Group C, giant prolactinomas, n = 17). Patients were followed for a mean of 7.5 years with sellar magnetic resonance imaging, visual fields and hormone measurements. Results Mean baseline prolactin was 767, 2090 and 24,806 ng/ml in Groups A, B and C, respectively (p < .01). Prolactin suppression below three times the upper limit of normal (ULN) was achieved in 34 (94%; mean weekly cabergoline dose of 1.2 mg), 37 (90%; cabergoline dose, 2.1 mg) and 15 (88%; cabergoline dose, 2.8 mg) men (p = .31) in each group. After excluding patients who underwent surgery and radiotherapy, cabergoline suppressed prolactin below three times ULN in 32/35 (91%), 29/37 (78%) and 11/14 (79%) men in Groups A, B and C, respectively (p = .27). Visual deficits were observed in 5 (14%), 12 (29%) and 10 (59%) patients (p < .01); improvement was achieved in 5/5 (100%), 11/12 (92%) and 10/10 (100%) of men in Groups A, B and C. Low baseline testosterone was measured in 26 (72%), 39 (95%) and 17 (100%) patients in the three groups (p < .01). Following multi‐modal treatment, hypogonadism persisted in 3 (8%), 5 (12%) and 2 (12%) men, respectively (p = .85). Conclusion Macroprolactinomas in men were controlled with cabergoline in 84% of cases, independent of tumour size. Pituitary surgery and adjuvant radiotherapy further improved long‐term response to 91%.

show abstract

Section: Discussioncontrasting

confidence: 68%

Long‐term response to cabergoline and multi‐modal treatment in men with macroprolactinoma: Does size really matter?

Rudman

Duskin-Bitan

Manisterski

et al. 2021

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…По данным М. Gruppetta и J. Vassallo [1], распространенность макроаденом составляла 40-67/100 000. Гигантские гипофизарные аденомы (более 40 мм) наблюдались в 4-8 % от всей когорты.…”

Section: распространенностьunclassified

Гігантські Аденоми Гіпофіза: Поширеність, Особливості Діагностики І Клінічного Перебігу

Urmanova

Alimova

2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

Огляд літератури /Literature Review/ Определение По классификации Всемирной организации здравоохранения 2004 г. выделяют только две разновидности опухолей гипофиза -аденому и аденокарциному. Доброкачественные опухоли гипофиза (аденомы) составляют около 10 % от всех внутричерепных новообразований. В литературе периодически проводятся систематизация и пересмотр различных классификаций аденом гипофиза и способов их лечения. Наиболее сложными для удаления являются гигантские аденомы. Летальность в этой группе больных достигает, по данным разных авторов, 20-30 % [1].Аденома гипофиза представляет собой опухоль эндокринной системы, проявлениями которой служат гипер-или гипосекреция гормонов передней доли гипофиза, а также клинические симптомы, вызванные воздействием новообразования на окружающие селлярную область анатомические структуры. Среди интракраниальных опухолей аденомы гипофиза занимают третье место, составляя от 7,3 до 18 % всех верифицированных опухолей мозга и

show abstract

“…The tumor MD of all planes (including coronal, sagittal and axial) was measured, and the tumor was categorized as a micro pituitary adenoma (<10 mm), large pituitary adenoma (10≤ MD <0 mm) or macro pituitary adenoma (≥40 mm), as described previously (21). The maximum coronal length (a) and the sagittal width (b) were measured on enhanced T1-weighted imaging, and the maximum height (c) was measured at the middle sella turcica (middle cavernous) in the coronal section.…”

Section: Patientsmentioning

confidence: 99%

Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the function of the prolactin/adenoma maximum diameter (PRL/MD) and the prolactin/adenoma volume (PRL/V) in the differential diagnosis of prolactinomas and other types of pituitary adenomas. A total of 118 patients with pituitary adenoma, hyperprolactinemia and a plasma PRL <250 µg/l were enrolled. Clinical data from these patients were retrospectively analyzed. A receiver operating characteristic curve was plotted. The function of PRL, PRL/MD and PRL/V in the differential diagnosis of prolactinomas and other types of pituitary adenomas was compared. The results revealed that a PRL of 55.65 µg/l was the most accurate [sensitivity (SE), 0.800; specificity (SP), 0.716; positive predictive value (PPV), 0.857; negative predictive value (NPV), 0.933; and Youden index (YI), 0.516]. The PRL/MD with the highest diagnostic value was 4.03 µg/(l x mm) (SE, 0.800; SP, 0.898; PPV, 0.727; NVP, 0.929; and YI, 0.698). The PRL/V with the highest diagnostic value was 54.00 µg/(l x cm 3 ) (SE, 0.900; SP, 0.966; PPV, 0.900; NVP, 0.966; and YI, 0.866). The PRL/MD tended to be of higher diagnostic accuracy than PRL, but this difference was not statistically significant (P= 0.097). The differentiation ability of PRL/V was significantly stronger than that of PRL (P=0.028). Thus, serum PRL, PRL/MD and PRL/V levels may be able to differentiate prolactinomas from other types of hyperprolactinemia-causing pituitary adenomas prior to treatment. PRL/V may be better than the PRL level in achieving a differential diagnosis, and the optimal PRL/V ratio for differentiating prolactinomas from other types of hyperprolactinemia-causing pituitary adenomas was 54.00 µg/(l x cm 3 ).

show abstract

Epidemiology and radiological geometric assessment of pituitary macroadenomas: population‐based study

Abstract: The various macroadenoma subtypes' epidemiological data are presented and differences between growth patterns among the various subtypes are highlighted.

Cited by 26 publications

References 27 publications

Long‐term response to cabergoline and multi‐modal treatment in men with macroprolactinoma: Does size really matter?

Long‐term response to cabergoline and multi‐modal treatment in men with macroprolactinoma: Does size really matter?

Гігантські Аденоми Гіпофіза: Поширеність, Особливості Діагностики І Клінічного Перебігу

Role of prolactin/adenoma maximum diameter and prolactin/adenoma volume in the differential diagnosis of prolactinomas and other types of pituitary adenomas

Contact Info

Product

Resources

About